Net margin is calculated as Net Income divided by its Revenue. Myriad Genetics's Net Income for the
three
months ended in Mar. 2026 was €-29.5 Mil. Myriad Genetics's Revenue for the
three
months ended in Mar. 2026 was €173.3 Mil. Therefore, Myriad Genetics's net margin for the quarter that ended in Mar. 2026 was -17.02%.
The historical rank and industry rank for Myriad Genetics's Net Margin % or its related term are showing as below:
STU:MYD'
s Net Margin % Range Over the Past 10 Years
Min: -48.24 Med: -9.57 Max: 17.92
Current: -48.24
STU:MYD's Net Margin % is ranked worse than 75.49% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.405
vs STU:MYD: -48.24
Myriad Genetics (STU:MYD) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Myriad Genetics Net Margin % Related Terms
Myriad Genetics Net Margin % Historical Data
* Premium members only.
The historical data trend for Myriad Genetics's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:MYD vs PRE, FLGT, IMDX: Net Margin % Comparison
For the Diagnostics & Research subindustry, Myriad Genetics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Myriad Genetics Net Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's Net Margin % distribution charts can be found below:
* The bar in red indicates where Myriad Genetics's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Myriad Genetics (STU:MYD) has a Net Margin % of -17.02% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Myriad Genetics and its competitors. According to the industry distribution chart, Myriad Genetics ranks #154 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 75.5%.
Is Myriad Genetics' Net Margin % too high?
Myriad Genetics' current Net Margin % is -17.02%. Based on the distribution chart, Myriad Genetics ranks #154 out of 204 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Myriad Genetics has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Myriad Genetics' Net Margin % compare to PRE and FLGT?
According to the Medical Diagnostics & Research industry distribution chart, Myriad Genetics ranks #154 out of 204 companies for Net Margin %. This places Myriad Genetics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Diagnostics & Research company?
A good Net Margin % depends on the Medical Diagnostics & Research industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Myriad Genetics and its competitors. Myriad Genetics's current Net Margin % is -17.02%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Myriad Genetics stock overvalued right now?
Based on GuruFocus' analysis, Myriad Genetics (STU:MYD) is currently considered Possible Value Trap. The stock's GF Value™ is €13.18, compared to a current price of €4.73 — trading 64.1% below its estimated fair value. The current Net Margin % is -17.02%. Myriad Genetics' overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Myriad Genetics (STU:MYD), the current Net Margin % is -17.02% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Myriad Genetics (STU:MYD) Overvalued in 2026?
Based on GuruFocus' analysis, Myriad Genetics stock appears to be undervalued.
The current stock price of €4.73 is trading 64.1% below its estimated GF Value™ of €13.18.
GuruFocus considers Myriad Genetics to be Possible Value Trap.
Key valuation signals for STU:MYD:
Net Margin %: -17.02%
GF Value™: €13.18 vs. price of €4.73 (64.1% below fair value)
No single metric tells the full story. See the STU:MYD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
53GF Score
Get the complete analysis for STU:MYD
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:MYD has been successfully added to your 
